Lumos Pharma Inc
Save
37.54M
Market cap
–
Current P/E
–
Forward P/E
About
Health care
Sector
Biotechnology
Industry
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
Similar securities
Based on sector and market capitalization
Report issue